DRUG DELIVERY SUPPLEMENT
OPHTHALMIC DELIVERY:
A smarter approach Nemera's e-Novelia: 0% preservatives + smart compliance = maximum compliance
I
t’s well known that the quality and success of a treatment can depend on patients’ adherence.
In 2016, the estimation of the revenues lost globally by pharma due to non-adherence was $637bn.1 In the case of ophthalmic therapy, the quality and safety of eye drop use for patients treated in a healthcare setting play a vital role in the delivery of healthcare. Underdosing, because of either poor adherence or poor performance, means that patients are not receiving their prescribed medication. Overdosing, as seen in a 2009 American Medical Association’s study, has the
potential for several problems, including systemic adverse events, ocular adverse events and a more rapid use of the bottle. 2 Today there is still a very poor compliance in administering drops into the eyes and a big room for improvement. A study in 2012 showed that nearly 9 of 10 glaucoma patients were unable to instil eye drops correctly, and this may be an important cause of unintentional noncompliance in glaucoma medical therapy.3 In order to improve their compliance to treatment, patients really need an innovative system to deliver their drops easily into
20
their eyes and limit negative side effects. That’s why at Nemera we’ve developed a multidose closing tip system which avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment. The system, called Novelia, limits the distribution of liquid to one drop at a time, with a precise and consistent drop size in order to improve patients’ adherence. The need for preservativefree medicines in the field of ophthalmology has been outlined by the European Medicines Agency (EMA). For instance,